-
1 Comment
Medical & Biological Laboratories Co., Ltd is currently in a long term downtrend where the price is trading 55.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.3.
Medical & Biological Laboratories Co., Ltd's total revenue rose by 19.6% to $3B since the same quarter in the previous year.
Its net income has increased by 137.9% to $596M since the same quarter in the previous year.
Based on the above factors, Medical & Biological Laboratories Co., Ltd gets an overall score of 3/5.
| CurrencyCode | EUR |
|---|---|
| ISIN | None |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | F |
| PE Ratio | 138.84 |
|---|---|
| Beta | 0.67 |
| Dividend Yield | 0.0% |
| Market Cap | 179M |
| Target Price | None |
Medical & Biological Laboratories Co., Ltd. researches, develops, manufactures, and sells in vitro diagnostics and research reagents worldwide. It offers in vitro diagnostics for allergies, autoimmune skin diseases, novel coronavirus, and polymyositis/dermatomyositis. The company was founded in 1969 and is headquartered in Nagoya, Japan. Medical & Biological Laboratories Co., Ltd. is a subsidiary of JSR Life Sciences, LLC.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MBW.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
